Division of Cardiology, Bangkok Hospital Khon Kaen, Bangkok Dusit Medical Services Plc., Khon Kaen, Thailand; Faculty of Medicine, Mahasarakham University, Mahasarakham, Thailand.
Department of Pediatrics, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailanda.
Anatol J Cardiol. 2023 Sep 1;27(9):504-512. doi: 10.14744/AnatolJCardiol.2023.3443. Epub 2023 Aug 21.
The benefits of prophylactic renal replacement therapy after cardiac catheterization in patients with chronic kidney disease remain unclear. The aim of this study is to confirm the benefit of prophylactic renal replacement therapy after cardiac catheterization.
We systematically searched for studies published from inception to December 2022 examining the benefits of prophylactic renal replacement therapy after cardiac catheterization in MEDLINE and EMBASE. Data analysis was performed according to the PRISMA statement using the Mantel-Haenszel method.
Five studies met the inclusion criteria, which comprised of 532 chronic kidney disease patients who underwent coronary angiography (268 had prophylactic renal replacement therapy and 264 did not have prophylactic renal replacement therapy). The pooled analysis revealed a non-significant decreased risk of 1-year mortality in chronic kidney disease patients who underwent coronary angiography and prophylactic renal replacement therapy compared to those who did not have prophylactic renal replacement therapy (RR = 0.59; P =.18; CI: 0.28-1.2795, I2 = 60.4%). The risk of hemodialysis during hospitalization and renal replacement therapy requirement in 1 year in chronic kidney disease patients who underwent coronary angiography and prophylactic renal replacement therapy were lower than in those who did not have prophylactic renal replacement therapy (RR = 0.13; P =.001; CI: 0.04-0.43, I2 = 9.1% and RR = 0.29; P =.015; CI: 0.11-0.78, I2 = 49.9%, respectively). The sensitivity analysis demonstrated that the overall findings remained consistent and did not significantly alter.
Prophylactic renal replacement therapy did not seem to lower 1-year mortality among chronic kidney disease patients who underwent coronary angiography. However, prophylactic renal replacement therapy appeared to reduce the risk of hemodialysis during hospitalization and renal replacement therapy requirement in 1 year.
在慢性肾脏病患者中,心脏导管术后预防性肾脏替代治疗的益处仍不清楚。本研究旨在证实心脏导管术后预防性肾脏替代治疗的益处。
我们系统地检索了从 MEDLINE 和 EMBASE 中发表的从开始到 2022 年 12 月的研究,以检查心脏导管术后预防性肾脏替代治疗的益处。根据 PRISMA 声明,使用 Mantel-Haenszel 方法进行数据分析。
五项研究符合纳入标准,共纳入 532 例接受冠状动脉造影的慢性肾脏病患者(268 例接受预防性肾脏替代治疗,264 例未接受预防性肾脏替代治疗)。荟萃分析显示,与未接受预防性肾脏替代治疗的患者相比,接受冠状动脉造影和预防性肾脏替代治疗的慢性肾脏病患者的 1 年死亡率降低,但无统计学意义(RR=0.59;P=.18;CI:0.28-1.2795,I2=60.4%)。接受冠状动脉造影和预防性肾脏替代治疗的慢性肾脏病患者住院期间需要血液透析和 1 年内需要肾脏替代治疗的风险低于未接受预防性肾脏替代治疗的患者(RR=0.13;P=.001;CI:0.04-0.43,I2=9.1%和 RR=0.29;P=.015;CI:0.11-0.78,I2=49.9%)。敏感性分析表明,总体结果保持一致,没有显著改变。
心脏导管术后预防性肾脏替代治疗似乎不能降低接受冠状动脉造影的慢性肾脏病患者的 1 年死亡率。然而,预防性肾脏替代治疗似乎可以降低住院期间血液透析和 1 年内需要肾脏替代治疗的风险。